Name: REVB Balance Sheet - Revelation Biosciences Assets & Debt | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Total Assets, Current Assets, Cash and Equivalents, Total Liabilities, Long-term Debt, Short-term Debt, Shareholders Equity, Working Capital, Book Value Per Share

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

REVB - Revelation Biosciences, Inc.

USD | NASDAQ | Healthcare

REVB Balance Sheet - Revelation Biosciences Assets & Debt | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash And Short Term Investments
Cash And Equivalents	10.7	6.5	12.0	5.3	1.3	0.0	-
Restricted Cash	-	-	-	-	-	-	-
Short Term Investments	-	-	-	-	-	0.5	-
Cash And Short Term Investments	10.7	6.5	12.0	5.3	1.3	0.5	-
Receivables
Accounts Receivable	-	-	-	-	-	-	-
Current Assets
Inventory	-	-	-	-	-	-	-
Prepaid Expenses	0.1	0.1	0.1	0.1	0.6	0.1	-
Non-Current Assets
Property, Plant & Equipment Gross	0.1	0.2	0.1	0.1	0.1	-	-
Accumulated Depreciation	0.1	0.1	0.1	0.0	0.0	-
Current Liabilities
Accounts Payable	0.6	0.8	1.4	0.6	0.6	0.0	-
Short Term Debt	-	-	-	-	-	-	-
Non-Current Liabilities
Long Term Debt	-	-	-	-	-	-	-
Operating Lease Liabilities Non-Current	0.7	0.0	-	-	-	-
Common Equity
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	-
Additional Paid In Capital	58.3	45.2	32.1	26.4	14.4	5.1
Supplementary Data
Total Debt	-	-	-	-	-	-	-
Net debt	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19
Cash And Short Term Investments
Cash And Equivalents	14.1	10.7	12.7	5.2	3.7	6.5	6.5	12.1	14.6	12.0	14.0	15.7	17.7	-	6.2

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Non-Current Liabilities
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Lease Liabilities Non-Current	0.6	0.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue Non-Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pension Obligations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.1	2.7	1.9	1.6	1.1	1.9	4.1	11.1	5.2	5.6	5.4	4.6	8.1	-	4.4	6.0

Common Equity
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-	-
Additional Paid In Capital	65.4	58.3	57.9	48.8	45.4	45.2	41.4	37.7	37.6	32.1	32.1	32.0	29.2	-	26.3	21.1	21.0
Retained Earnings	(52.4)	(49.4)	(46.9)	(45.0)	(42.6)	(40.5)	(38.8)	(36.5)	(28.1)	(25.5)	(23.3)	(20.6)	(19.2)	-	(24.1)	(23.0)	(21.1)
Accumulated Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders Equity	13.0	8.9	11.0	3.8	2.9	4.7	2.7	1.1	9.5	6.6	8.8	11.4	10.0	-	2.2	(1.8)	(0.1)
Total Equity	13.0	8.9	11.0	3.8	2.9	4.7	2.7	1.1	9.5	6.6	8.8	11.4	10.0	-	2.2	(1.8)	(0.1)	(0.1)

Supplementary Data
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Working Capital	12.8	8.8	11.0	3.8	2.8	4.7	2.6	1.1	9.4	6.6	8.7	11.3	9.9	-	2.1	(1.9)	(0.2)	(0.2)
Book Value	13.0	8.9	11.0	3.8	2.9	4.7	2.7	1.1	9.5	6.6	8.8	11.4	10.0	-	2.2	(1.8)	(0.1)	(0.1)
Tangible Book Value	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-